Correction to: Reflections on FDA Draft Guidance for Products Containing Nanomaterials: Is the Abbreviated New Drug Application (ANDA) a Suitable Pathway for Nanomedicines?

Emily Marden; Ioanna Ntai; Scott Bass; Beat Flühmann

doi:10.1208/s12248-018-0265-y

Correction to: Reflections on FDA Draft Guidance for Products Containing Nanomaterials: Is the Abbreviated New Drug Application (ANDA) a Suitable Pathway for Nanomedicines?

AAPS J. 2018 Sep 25;20(6):104. doi: 10.1208/s12248-018-0265-y.

Authors

Emily Marden¹, Ioanna Ntai², Scott Bass³, Beat Flühmann⁴

Affiliations

¹ Food, Drug and Medical Device Regulatory Law, Sidley Austin LLP, Palo Alto, California, USA.
² Non-Biological Complex Drugs, Vifor Pharma Ltd., Flughofstrasse 61, 8152, Opfikon, Switzerland.
³ Global Life Sciences, Sidley Austin LLP, Washington, D.C., USA.
⁴ Non-Biological Complex Drugs, Vifor Pharma Ltd., Flughofstrasse 61, 8152, Opfikon, Switzerland. beat.fluehmann@viforpharma.com.

PMID: 30255312
DOI: 10.1208/s12248-018-0265-y

Abstract

In the published article the given name and the family name for each author is listed in the incorrect order and therefore cited incorrectly. The correct order (given name followed by family name) of names is listed above.

Publication types

Published Erratum